Literature DB >> 25096190

Is a prospective trial necessary to suggest a clinical relevance?

Johan Pallud1, Hugues Duffau1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25096190      PMCID： PMC4136901          DOI： 10.1093/neuonc/nou156

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

Review 1.  Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: a plea for systematic measurement of growth rates.

Authors:  Johan Pallud; Luc Taillandier; Laurent Capelle; Denys Fontaine; Matthieu Peyre; François Ducray; Hugues Duffau; Emmanuel Mandonnet
Journal:  Neurosurgery       Date:  2012-09       Impact factor: 4.654

2.  Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.

Authors:  Matthieu Peyre; Stéphanie Cartalat-Carel; David Meyronet; Damien Ricard; Anne Jouvet; Johan Pallud; Karima Mokhtari; Jacques Guyotat; Emmanuel Jouanneau; Marie-Pierre Sunyach; Didier Frappaz; Jérôme Honnorat; François Ducray
Journal:  Neuro Oncol       Date:  2010-05-20       Impact factor: 12.300

3.  Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities.

Authors:  J Pallud; P Varlet; B Devaux; S Geha; M Badoual; C Deroulers; P Page; E Dezamis; C Daumas-Duport; F-X Roux
Journal:  Neurology       Date:  2010-05-25       Impact factor: 9.910

4.  Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.

Authors:  Johan Pallud; Marie Blonski; Emmanuel Mandonnet; Etienne Audureau; Denys Fontaine; Nader Sanai; Luc Bauchet; Philippe Peruzzi; Marc Frénay; Philippe Colin; Rémy Guillevin; Valérie Bernier; Marie-Hélène Baron; Jacques Guyotat; Hugues Duffau; Luc Taillandier; Laurent Capelle
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

5.  Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Authors:  Catherine Gozé; Marie Blonski; Guillaume Le Maistre; Luc Bauchet; Edouard Dezamis; Philippe Page; Pascale Varlet; Laurent Capelle; Bertrand Devaux; Luc Taillandier; Hugues Duffau; Johan Pallud
Journal:  Neuro Oncol       Date:  2014-05-20       Impact factor: 12.300

6.  1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.

Authors:  Catherine Gozé; Charlotte Bezzina; Eric Gozé; Valérie Rigau; Thierry Maudelonde; Luc Bauchet; Hugues Duffau
Journal:  J Neurooncol       Date:  2012-03-06       Impact factor: 4.130

7.  Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas.

Authors:  Johan Pallud; Emmanuel Mandonnet; Hugues Duffau; Michèle Kujas; Rémy Guillevin; Damien Galanaud; Luc Taillandier; Laurent Capelle
Journal:  Ann Neurol       Date:  2006-09       Impact factor: 10.422

8.  Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.

Authors:  Emmanuel Mandonnet; Johan Pallud; Denys Fontaine; Luc Taillandier; Luc Bauchet; Philippe Peruzzi; Jacques Guyotat; Valérie Bernier; Marie-Hélène Baron; Hugues Duffau; Laurent Capelle
Journal:  Neurosurg Rev       Date:  2009-10-22       Impact factor: 3.042

9.  Dynamic history of low-grade gliomas before and after temozolomide treatment.

Authors:  Damien Ricard; Gentian Kaloshi; Alexandra Amiel-Benouaich; Julie Lejeune; Yannick Marie; Emmanuel Mandonnet; Michèle Kujas; Karima Mokhtari; Sophie Taillibert; Florence Laigle-Donadey; Antoine F Carpentier; Antonio Omuro; Laurent Capelle; Hugues Duffau; Philippe Cornu; Rémy Guillevin; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

10.  Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas.

Authors:  Chadi Hlaihel; Laurent Guilloton; Jacques Guyotat; Nathalie Streichenberger; Jerome Honnorat; François Cotton
Journal:  J Neurooncol       Date:  2009-08-29       Impact factor: 4.130
  10 in total
  1 in total

1.  Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma - A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy.

Authors:  Roland Roelz; David Strohmaier; Ramazan Jabbarli; Rainer Kraeutle; Karl Egger; Volker A Coenen; Astrid Weyerbrock; Peter C Reinacher
Journal:  Sci Rep       Date:  2016-08-30       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.